Skip to main content
Top
Published in: Critical Care 1/2004

01-02-2004 | Poster presentation

Early treatment with Drotrecogin alfa (activated) was associated with reduced hospital resource use in adult severe sepsis patients with two or more organ dysfunctions at baseline: results from ENHANCE

Authors: J Vincent, J Dhainaut, C Putensen, A Artigas, R Fumagalli, M Turlo, K Wong, J Janes

Published in: Critical Care | Special Issue 1/2004

Login to get access

Excerpt

In a phase 3 trial (PROWESS, n = 1690), Drotrecogin alfa (activated) (DrotAA) was associated with a significant survival improvement and favorable benefit–risk profile compared with placebo in adult patients with severe sepsis receiving standard supportive care. A global, single-arm, open-label trial of DrotAA in adult patients with severe sepsis (ENHANCE, n = 2378) was subsequently conducted at 361 sites in 25 countries, and hospital resource usage was assessed with respect to the timing of DrotAA administration. …
Metadata
Title
Early treatment with Drotrecogin alfa (activated) was associated with reduced hospital resource use in adult severe sepsis patients with two or more organ dysfunctions at baseline: results from ENHANCE
Authors
J Vincent
J Dhainaut
C Putensen
A Artigas
R Fumagalli
M Turlo
K Wong
J Janes
Publication date
01-02-2004
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 1/2004
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc2584

Other articles of this Special Issue 1/2004

Critical Care 1/2004 Go to the issue